Ideaya Biosciences (IDYA) announced the appointment of Theodora Ross into the newly created role of chief development officer. In this role, Ross will be responsible for leading early clinical development for Ideaya’s emerging oncology pipeline and play a role in guiding the company’s long-term R&D strategy. Ross joins Ideaya from AbbVie (ABBV), where she served as VP, head of early oncology R&D and site head for the Bay Area.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on IDYA:
- IDEAYA Biosciences: Pipeline Progress and Late-Stage Clinical Expansion Support Reiterated Buy Rating
- Ideaya Biosciences price target raised to $65 from $64 at Citi
- Ideaya Biosciences price target raised to $52 from $49 at Wedbush
- IDEAYA Biosciences: Buy Rating on Darovasertib/Crizotinib Ahead of Pivotal OpतimUM-02 Readout and Supported by Strong Cash Runway
- Ideaya Biosciences reports Q4 EPS (94c), consensus (95c)